FDA Leaves Avandia on the Market. What you should tell your patients.

Statement Warns Against Stopping Avandia Use.

The Los Angeles Times (7/15, Maugh) reported, "Diabetics taking Avandia [rosiglitazone] who are concerned about the drug following Wednesday's decision by a Food and Drug Administration advisory committee to allow it to remain on the market should continue taking the drug until they can make arrangements with their physician to receive alternatives, three groups of physicians who treat diabetes said Thursday." Notably, "the Endocrine Society, the American Diabetes Assn. and the American Assn. of Clinical Endocrinologists issued a joint statement saying that the risk of stopping the drug abruptly is greater than any potential risk of cardiovascular disease that might be caused by the drug."

According to HealthDay (7/15, Gardner), "'Patients should continue taking all currently prescribed medications unless instructed otherwise by their health care provider,' Dr. Robert A. Vigersky, immediate past president of the Endocrine Society, said in the statement." The statement also pointed out that "reports regarding the cardiovascular safety of rosiglitazone...have not been definitive."

Reuters (7/16, Fox) also quotes Dr. Vigersky, who stated, "Stopping diabetes medications can cause significant harm and result in higher levels of blood glucose that may cause severe short term health problems and could increase the risk of diabetes-related complications in the long term."

CNN (7/15, Rice) provided an "explanation of the pros and cons of other treatments to lower blood sugar for people with type 2 diabetes," including metformin, metformin with sulfonylureas, metformin with insulin, Actos [pioglitazone], DPP-4 inhibitors, and diet and exercise.